25 May 2013
Keywords: gsk, decides, license, exelixis, xl184, uk, drug
Article | 10 November 2008
UK drug major GlaxoSmithKline says it will not exercise its option to license Exelixis' XL184 nor any of the earlier ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 November 2008
24 May 2013
© 2013 thepharmaletter.com